Melanoma Mortality Rates Decreasing Despite Ongoing Increase in Incidence Rates
The American Cancer Society (ACS) released the latest estimates about the number of cancer patients in its annual report, Cancer Facts and Figures. This report highlights the incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for cancer in the United States. Importantly, the report tracks trends over time – allowing us to monitor the impact of improvements to prevention and treatment approaches.
2019 Melanoma Facts and Figures:
- In 2019 in the US, an estimated 96,480 new cases of melanoma will be diagnosed, impacting 57,220 men and 39,260 women;
- In 2019 in the US, an estimated 7,230 deaths from melanoma are expected, comprised of 4,740 men and 2,490 women;
- The incidence of melanoma of the skin has risen rapidly over the past 30 years, with the incidence rate of melanoma increasing 3% per year from 2006 to 2015 among men and women ages 50 and older; but the incidence rate was stable in people younger than 50 during this same time period.
This data is incredibly useful for understanding trends in melanoma statistics over time and how melanoma research and new treatments – such as advances in immunotherapy and targeted therapy – may be impacting survival and outcomes across the entire population, not just in clinical trials.
Trends in mortality rates from melanoma, as reported, declined from 2007 to 2016. During this time period, the death rate for melanoma declined by about 2% per year in adults 50 years of age and older and by about 4% per year in those younger than 50. These data suggest that the several new treatments for melanoma approved over the last decade appear to be improving survival, and reducing mortality rates across the population. However, with an estimated 7,230 deaths this year from melanoma, more research is needed to develop new treatment options for all patients. Understanding the urgent need for new melanoma treatments, MRA has invested more than 90% of its research funding to date into the discovery and development of new treatments ($91 million of $101 million), including more than 96 unique new treatment approaches.
The new report from ACS shows that melanoma is the fifth most commonly diagnosed cancer in the U.S. among both men and women. More research is needed to understand the factors that increase a person’s risk and the most useful prevention strategies. MRA included research into early detection and prevention as an additional priority area in our most request solicitation for research proposals. New MRA melanoma research awards – in prevention, detection and developing new treatments – will be announced in the spring 2019.